Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

GlobeNewswire March 7, 2023

Zevra Therapeutics to Present at 35th Annual Roth Conference

GlobeNewswire March 6, 2023

Zevra Therapeutics Begins Trading as ZVRA

GlobeNewswire March 1, 2023

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

GlobeNewswire February 28, 2023

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

GlobeNewswire February 27, 2023

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

GlobeNewswire February 27, 2023

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium(TM) 2023

GlobeNewswire February 24, 2023

Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium(TM) 2023

GlobeNewswire February 23, 2023

CORRECTION - KemPharm Announces Corporate Name Change to Zevra Therapeutics

GlobeNewswire February 22, 2023

KemPharm Announces Corporate Name Change to Zevra Therapeutics

GlobeNewswire February 22, 2023

KemPharm Enhances Senior Management Team

GlobeNewswire January 31, 2023

KemPharm Issues Letter to Shareholders

GlobeNewswire January 24, 2023

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

GlobeNewswire January 18, 2023

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

GlobeNewswire January 11, 2023

KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

GlobeNewswire January 9, 2023

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

GlobeNewswire December 21, 2022

KemPharm Announces Appointment of Christopher Posner as New Independent Director

GlobeNewswire November 29, 2022

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

GlobeNewswire November 18, 2022

KemPharm Reports Third Quarter 2022 Results

GlobeNewswire November 9, 2022

KemPharm to Report Third Quarter 2022 Financial Results

GlobeNewswire November 1, 2022